Use of nitisinone in patients with alkaptonuria

Metabolism: Clinical and Experimental

Volumn 54, Issue 6, 2005, Pages 719-728

  Suwannarat, Pim ^a   O'Brien, Kevin ^a,b   Perry, Monique B ^c   Sebring, Nancy ^c   Bernardini, Isa ^a   Kaiser Kupfer, Muriel I ^d   Rubin, Benjamin I ^d   Tsilou, Ekaterina ^d   Gerber, Lynn H ^c   Gahl, William A ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AZITHROMYCIN; CHOLINE MAGNESIUM TRISALICYLATE; DOCUSATE SODIUM; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IBUPROFEN; IRON; MEVINOLIN; NITISINONE; OMEPRAZOLE; OXYCODONE; PARACETAMOL; SALBUTAMOL; TYROSINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALKAPTONURIA; AMINO ACID BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AORTA STENOSIS; ARTHRALGIA; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA DISEASE; DIET; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; EYE TOXICITY; FEMALE; FLANK PAIN; HUMAN; LIVER TOXICITY; MALE; NEPHROLITHIASIS; OPHTHALMOLOGY; PRIORITY JOURNAL; PROTEIN RESTRICTION; SKIN DISEASE; VOMITING;

ADULT; AGED; ALKAPTONURIA; CYCLOHEXANONES; DIETARY PROTEINS; FEMALE; HOMOGENTISIC ACID; HUMANS; MALE; MIDDLE AGED; NITROBENZOATES; TYROSINE;

EID: 21144458162     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.12.017     Document Type: Article

References (26)

1. B.N. LaDu Alkaptonuria 8th ed C.R. Scriver A.L. Beaudet W.S. Sly D. Valle B. Vogelstein The Metabolic and Molecular Bases of Inherited Disease vol. 2 2001 McGraw-Hill New York 2109 2123
2. C. Phornphutkul, W.J. Introne, and M.B. Perry Natural history of alkaptonuria N. Engl. J. Med. 347 2002 2111 2121
3. M.R. Pollak, Y.-H.W. Chou, and J.J. Cerda Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2 Nat. Genet. 5 1993 201 204
4. S. Janocha, W. Wolz, and S. Srsen The human gene for alkaptonuria (AKU) maps to chromosome 3q Genomics 19 1994 5 8
5. J.M. Fernandez-Canon, B. Granadino, and D. Beltran-Valero de Bernabe The molecular basis of alkaptonuria Nat. Genet. 14 1996 19 24
6. R.R. Sealock, M. Gladstone, and J.M. Steele Administration of ascorbic acid to an alkaptonuric patient Proc. Soc. Exp. Biol. Med. 44 1940 580 583
7. Y. Anikster, W.L. Nyhan, and W.A. Gahl NTBC and alkaptonuria Am. J. Hum. Genet. 63 1998 920 921
8. G.A. Mitchell, M. Grompe, M. Lambert, and R.M. Tanguay Hypertyrosinemia 8th ed. C.R. Scriver A.L. Beaudet W.S. Sly D. Valle B. Vogelstein The Metabolic and Molecular Bases of Inherited Disease vol. 2 2001 McGraw-Hill New York 1777 1805
9. S. Lindstedt, E. Holme, and E.A. Lock Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase Lancet 340 1992 813 817
10. E. Holme, and S. Lindstedt Tyrosinemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione) J. Inherit. Metab. Dis. 21 1998 507 517
11. P. Schober Ledenwirbel saoule und kreuzachmerchen Munch. Med. Wochenschr. 84 1937 366
12. I.F. Macrae, and V. Wright Measurement of back movement Ann. Rheum. Dis. 28 1969 584
13. J.E. Ware Choosing measures of health status for individual in general populations Am. J. Public Health 71 1981 620 625
14. J.E. Ware, and C.D. Sherbourne The MOS 36-Item Short Form Health Survey. SF-36. SF-36. Conceptual framework and item selection Med. Care 30 1992 473 483
15. T.J. Lustberg, J.D. Schulman, and J.E. Seegmiller The preparation and identification of various adducts of oxidized homogentisic acid and the development of a new sensitive colorimetric assay for homogentisic acid Clin. Chim. Acta 35 1971 325 333
16. T.C. Markello, I. Bernardini, and W.A. Gahl Improved renal function in children with cystinosis treated with cysteamine N. Engl. J. Med. 328 1993 1157 1162
17. K. Sadilkova, R.M. Jack, and R.C. Scott Quantification of NTBC (Nitisinone, Orfadine) in human plasma by LC-ESI-MS/MS Poster Presentation, American Society of Mass Spectrometry 2003
18. S.F. Schakel Maintaining a nutrient database in a changing marketplace: Keeping pace with changing food products-a research perspective J. Food Compos. Anal. 14 2001 315 322
19. M.B. Perry, C. Phornphutkul, G.P. Furst, M.D. Murphey, W.A. Gahl, and L.H. Gerber Physical and functional performance in alkaptonuria Arch. Phys. Med. Rehabil. 84 9 2003 E6
20. M.B. Perry, W.J. Introne, G.P. Furst, W.A. Gahl, and L.H. Gerber Impairments and functional limitations in alkaptonuria Arch. Phys. Med. Rehabil. 82 9 2001 1298
21. M.G. Hall, M.F. Wilks, W.M. Provan, S. Eksborg, and B. Lumholtz Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl) -1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenylpyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers Br. J. Clin. Pharmacol. 52 2001 169 177
22. P. Gissen, M.A. Preece, H.A. Willshaw, and P.J. Mckierman Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC J. Inherit. Metab. Dis. 26 2003 13 16
23. M.S. Macsai, T.L. Schwartz, D. Hinkle, M.B. Hummel, M.G. Mulhern, and D. Rootman Tyrosinemia type II: Nine cases of ocular signs and symptoms Am. J. Ophthalmol. 132 2001 522 527
24. U. Ruetschi, R. Cerone, and C. Perez-Cerda Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III Hum. Genet. 106 2000 654 662
25. C.A. Dujovne Side effects of statins: Hepatitis versus "transaminitis"-myositis versus "CPKitis" Am. J. Cardiol. 89 2002 1411 1413
26. K.G. Tolman Reply to Dr. Dujovne's editorial Am. J. Cardiol. 89 2002 1452